Celularity Inc. (CELU) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Celularity Inc. (CELU) Healthcare & Pipeline Overview

Celularity Inc. is pioneering off-the-shelf placental-derived cell therapies, targeting cancer and other diseases, with a diverse clinical pipeline and a commitment to innovative regenerative medicine solutions.

What Is the Investment Thesis for CELU?

Celularity Inc. is positioned for growth through its innovative approach to cell therapy, targeting significant market opportunities in oncology and regenerative medicine. The company’s lead programs, including CYCART-19 and CYNK-001, are in various stages of clinical trials, with potential market sizes in the billions for oncology therapies alone. The global CAR-T cell therapy market is projected to reach $9.5 billion by 2027, while the NK cell therapy market is also expected to grow substantially. Celularity's unique placental-derived therapies offer competitive advantages in terms of accessibility and scalability, potentially leading to faster commercialization timelines. However, risks include regulatory challenges and the competitive landscape, which could impact the pace of clinical development and market entry. The company's ability to navigate these challenges while advancing its clinical pipeline will be critical in driving shareholder value.

Based on FMP financials and quantitative analysis

CELU Key Highlights

Market cap of $0.02 billion reflects the early-stage nature of the company.

• Profit margin of -345.4% indicates substantial investment in R&D as it develops its clinical pipeline.
• Gross margin of 76.0% suggests high potential profitability once products are commercialized.
• Beta of 0.45 indicates lower volatility compared to the broader market, appealing to risk-averse investors.
• No dividend yield as the company reinvests earnings into growth initiatives.

Who Are CELU's Competitors?

CELU is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CELU's Key Strengths?

Innovative approach leveraging placental-derived cells for therapy.

• Strong clinical pipeline with multiple promising candidates.
• High gross margin potential once therapies are commercialized.
• Established brand in bio-banking and cell storage services.

What Are CELU's Weaknesses?

Negative profit margins due to heavy R&D investments.

• Limited market presence compared to larger competitors.
• Dependence on successful clinical trial outcomes for growth.
• Relatively small employee base may limit operational scalability.

What Could Drive CELU Stock Higher?

Results from Phase I clinical trials for CYCART-19 expected in late 2026.

• Initiation of Phase I/IIa trials for CYNK-001 in glioblastoma multiforme anticipated by Q4 2026.
• Development of APPL-001 and PDA-002 in pre-clinical stages, with potential for future clinical trials.
• Expansion of LifebankUSA services to enhance bio-banking revenue streams.
• Continued partnerships with healthcare providers to broaden market reach.

What Are the Key Risks for CELU?

Financial-distress signal — its Altman Z-Score of -15.89 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $11.0M recently.
• Regulatory challenges could delay the approval of key therapies.
• Competition from established biotech firms may impact market share.
• Clinical trial failures could adversely affect the company's future prospects.
• Changes in healthcare policies may influence reimbursement for cell therapies.

What Are the Growth Opportunities for CELU?

• Expansion of CYCART-19: Celularity's lead CAR-T therapy is currently in Phase I trials, targeting B-cell malignancies. The global CAR-T market is projected to grow to $9.5 billion by 2027, providing a substantial revenue opportunity if the therapy successfully advances through clinical trials and gains regulatory approval.
• Development of CYNK-001: This placental-derived NK cell therapy is in Phase I trials for acute myeloid leukemia and glioblastoma. The NK cell therapy market is expected to grow significantly, with increasing recognition of its potential in oncology, presenting a lucrative opportunity for Celularity.
• Market for surgical and wound care products: Celularity's existing products like Biovance and Interfyl cater to the surgical and wound care markets, which are projected to grow due to an aging population and increased surgical procedures. This segment could provide steady revenue streams while the company develops its more experimental therapies.
• BioBanking services growth: With the increasing demand for stem cell storage services, Celularity's LifebankUSA brand is positioned to capture a growing market. The global stem cell banking market is expected to expand, driven by rising awareness and advancements in regenerative medicine.
• Pre-clinical advancements: The development of APPL-001 and PDA-002 for Crohn's disease and muscular dystrophy, respectively, could open new therapeutic avenues. As these conditions have limited treatment options, successful development could lead to significant market opportunities.

What Threats Does CELU Face?

• Intense competition from established biotechnology firms.
• Regulatory hurdles in obtaining approvals for new therapies.
• Market volatility affecting funding for clinical trials.
• Rapid technological advancements may outpace current offerings.

What Are CELU's Competitive Advantages?

• Unique focus on placental-derived cell therapies, differentiating it from competitors.
• Strong intellectual property portfolio protecting its innovative therapies.
• Established brand recognition in the bio-banking sector through LifebankUSA.
• Robust clinical pipeline with multiple therapies in various stages of development.
• Experienced leadership team with a track record in biotechnology and regenerative medicine.

What Does CELU Do?

Founded in 2016 and headquartered in Florham Park, New Jersey, Celularity Inc. is a clinical-stage biotechnology company dedicated to developing off-the-shelf placental-derived allogeneic cell therapies. The company operates through three primary segments: Cell Therapy, Degenerative Disease, and BioBanking. Its innovative approach leverages the unique properties of placental cells, which are rich in stem cells, to create therapies that can potentially transform the treatment landscape for cancer, immune disorders, and infectious diseases. Celularity's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy currently in Phase I clinical trials for B-cell malignancies. Additionally, CYNK-001, an unmodified natural killer (NK) cell therapy, is being evaluated in Phase I trials for acute myeloid leukemia and in Phase I/IIa trials for glioblastoma multiforme and COVID-19. The company also has CYNK-101, a genetically modified NK cell therapy in Phase I clinical trials for HER2+ gastric and gastroesophageal cancers, as well as APPL-001 and PDA-002, both in pre-clinical stages for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. Beyond its therapeutic developments, Celularity offers products for surgical and wound care markets, such as Biovance and Interfyl, and provides stem cell storage services under the LifebankUSA brand. With a focus on innovation and a commitment to addressing unmet medical needs, Celularity is positioned to make significant contributions to the field of regenerative medicine.

What Products and Services Does CELU Offer?

• Develops placental-derived allogeneic cell therapies for cancer and other diseases.
• Operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
• Conducts clinical trials for innovative therapies targeting various malignancies and diseases.
• Sells and licenses products for surgical and wound care markets.
• Provides stem cell collection and storage services under LifebankUSA.
• Focuses on regenerative medicine with a commitment to addressing unmet medical needs.

How Does CELU Make Money?

• Generates revenue through the sale of surgical and wound care products.
• Offers stem cell storage services, creating a recurring revenue stream.
• Licenses its innovative therapies to other healthcare providers and institutions.
• Engages in clinical trials to develop and commercialize new therapies, aiming for regulatory approvals.
• Explores partnerships and collaborations to expand its market reach and enhance product offerings.

What Industry Does CELU Operate In?

The biotechnology industry is experiencing rapid growth, driven by advancements in genetic therapies and a rising demand for innovative treatment solutions. The global biotechnology market is expected to reach $2.4 trillion by 2028, with significant investments flowing into cell and gene therapies. Celularity Inc. operates within this dynamic landscape, focusing on placental-derived therapies, a niche that sets it apart from traditional cell therapy companies. As the demand for effective cancer treatments continues to rise, Celularity's innovative approach positions it favorably against competitors who are also vying for market share in the oncology and regenerative medicine sectors.

Who Are CELU's Key Customers?

• Healthcare providers seeking innovative therapies for cancer treatment.
• Patients requiring advanced wound care solutions.
• Research institutions focused on regenerative medicine.
• Hospitals and clinics utilizing stem cell storage services.
• Biotechnology firms interested in licensing innovative cell therapies.

Celularity Inc. Financial Trajectory

Celularity Inc. (CELU) reported $4.1M in revenue for Q4 FY2025, a decline of 22.3% compared to the prior quarter. The company recorded a net loss of $24.4M, with diluted EPS of $-0.95. Revenue has contracted over three consecutive quarters, which investors in this unknown Healthcare stock should monitor closely. Across the four most recent quarters, CELU averaged $-0.92 in diluted EPS.

Company Profile

Celularity Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Florham Park, US. The company is led by CEO Robert Joseph Hariri. CELU has traded publicly since 2019.

How Celularity Inc. Is Valued

Relative to its peer group, CELU's quantitative score of 22/100 is below the peer average of 92/100.

Return on equity for Celularity Inc. stands at 411.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -85.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -92.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.15 means current liabilities exceed short-term assets, a liquidity point worth watching.

Celularity Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.89 places it in the distress zone, a signal of elevated financial risk.

Celularity Inc. has beaten Wall Street's EPS estimate in 6 of its last 6 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 45.8% above estimates on average.

Wall Street analysts project Celularity Inc. revenue of about $44.0M for fiscal 2026, with EPS near $-2.75.

Over the past six months, Celularity Inc. insiders filed 15 SEC Form 4 transactions — 12 sales and 3 purchases. On net that is roughly 6.1M shares disposed (about $11.0M), a signal worth weighing alongside the fundamentals.

CELU Financials

CELU Latest News

CELU Analyst Consensus

CELU MoonshotScore

Latest Celularity Inc. Analysis

Celularity Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources